MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.05
+0.12 (+6.22%)
At close: 4:00PM EDT

2.05 0.00 (0.00%)
After hours: 5:58PM EDT

Stock chart is not supported by your current browser
Previous Close1.93
Open1.93
Bid2.00 x 3200
Ask2.05 x 1400
Day's Range1.90 - 2.19
52 Week Range0.98 - 4.45
Volume7,815,141
Avg. Volume4,910,918
Market Cap313.625M
Beta (3Y Monthly)3.29
PE Ratio (TTM)N/A
EPS (TTM)-0.99
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    Today’s Research Reports on Stocks to Watch: Altimmune and MannKind

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...

  • Why MannKind Corp. Soared 16.4% Tuesday
    Motley Fool2 days ago

    Why MannKind Corp. Soared 16.4% Tuesday

    The company has completed its planned transaction with United Therapeutics.

  • GlobeNewswire3 days ago

    United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

    United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

  • PR Newswire3 days ago

    United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement

    RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

  • GlobeNewswire4 days ago

    Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, was recently awarded top honors for its first Afrezza® TV commercial, “Unexpected Moments,” at the Medical Marketing & Media (MM&M) awards ceremony last week. The company worked with precisioneffect, a Boston-based healthcare advertising agency, to produce the advertisement. “Managing mealtime control is crucial in order to help individuals living with diabetes optimize their outcomes,” said Michael Castagna, CEO of MannKind Corporation.

  • Here's What Sent MannKind Corporation Soaring 66.4% in September
    Motley Fool7 days ago

    Here's What Sent MannKind Corporation Soaring 66.4% in September

    A new collaboration agreement breathed life into the troubled manufacturer of inhaled insulin powder.

  • GlobeNewswire15 days ago

    MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, presented data from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with type 1 diabetes on multiple daily injections) at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. The STAT study is the first randomized, controlled study to assess diabetes control using continuous glucose monitoring (CGM) and Afrezza® in individuals with type 1 diabetes.

  • GlobeNewswire16 days ago

    MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes

    MannKind Corporation (MNKD), announced that it presented new scientific data in an oral and poster presentation at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. PS 097) both took place Tuesday, October 2, 2018.

  • MannKind Stock History
    Motley Fool21 days ago

    MannKind Stock History

    Here's the full story of how this biopharma got to where it is today.

  • GlobeNewswire25 days ago

    MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients

    MannKind Corporation (MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients is now open for enrollment. The first group of individuals participating in the ongoing pediatric study of Afrezza, which included adolescents with type 1 diabetes aged 13-17 years old, was recently completed. The study findings to date support that the single‑dose pharmacokinetic (PK) profile of insulin levels for this age group is consistent with patterns seen in adult patients.  In addition, dosing over a one‑month period demonstrated a safety profile consistent with that observed in adults.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT

    Q2 2018 MannKind Corp Earnings Call

  • GlobeNewswirelast month

    Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics

    WESTLAKE VILLAGE, Calif., Sept. 13, 2018-- MannKind Corporation announced today that "Improved Postprandial Glucose with Inhaled Technosphere ® Insulin Compared to Insulin Aspart in Patients with ...

  • Implied Volatility Surging for MannKind (MNKD) Stock Options
    Zackslast month

    Implied Volatility Surging for MannKind (MNKD) Stock Options

    MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRElast month

    Mannkind Afrezza Sales Have Doubled and Treprostinil is Getting Some Traction

    NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. On September 4th, MannKind announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. MNKD doubled its market share over the past year as a result of its commercialization efforts and are excited about its new Afrezza clinical data being released throughout 2018.

  • Motley Foollast month

    Is MannKind Corporation Stock a Buy?

    A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Big news lit a fire under these biotech stocks this week. But can their momentum continue?

  • Motley Foollast month

    A New Deal Moves MannKind Back From the Brink

    A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker Amarin.

  • The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
    Zackslast month

    The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

    The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

  • InvestorPlacelast month

    New Development Partnership Could Pay Off Big for MannKind Stock

    After spending much of 2017 in a downtrend, MannKind (NASDAQ:MNKD) lit up on the stock market and closed above $2.00 a share on Sept. 4 for the first time since June. The company announced that it would collaborate with United Therapeutics (NASDAQ:UTHR) on treprostinil, an investigational drug for the treatment of pulmonary arterial hypertension. The cash infusion from the deal is just what MannKind needed.

  • Why Cronos Group, MannKind, and Vera Bradley Jumped Today
    Motley Foollast month

    Why Cronos Group, MannKind, and Vera Bradley Jumped Today

    Find out the latest buzz on these winners.

  • MannKind Stock Up on Licensing Deal With United Therapeutics
    Zackslast month

    MannKind Stock Up on Licensing Deal With United Therapeutics

    MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

  • The Probable Reason Why MannKind Corporation Is Rallying Again
    Motley Foollast month

    The Probable Reason Why MannKind Corporation Is Rallying Again

    Shares soar for the second day in a row. What can explain the bullish move?

  • Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars
    Zackslast month

    Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

    Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.

  • United Therapeutics Enters into a Collaboration with MannKind
    Market Realistlast month

    United Therapeutics Enters into a Collaboration with MannKind

    United Therapeutics and MannKind’s collaboration is for an investigational treprostinil dry powder that is presently in clinical trials. According to the terms of the agreement, United Therapeutics (UTHR) is responsible for the development, regulatory activities, and commercialization of this dry powder.

  • Why MannKind Stock Is Skyrocketing Today
    InvestorPlacelast month

    Why MannKind Stock Is Skyrocketing Today

    The good news for MNKD stock comes in the form of an agreement to have it manufacture a dry powder formulation of treprostinil. This is a drug that is currently in testing for treating pulmonary arterial hypertension. The deal will have MannKind acting as the manufacturer for clinical supplies of the drug and its initial commercial run. For its efforts, the company is getting an upfront payment of $45 million.